Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rifapentine
Drug ID BADD_D01937
Description Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Indications and Usage For the treatment of pulmonary tuberculosis.
Marketing Status approved; investigational
ATC Code J04AB05
DrugBank ID DB01201
KEGG ID D00879
MeSH ID C018421
PubChem ID 135403821
TTD Drug ID D0G9IU
NDC Product Code 40074-0009; 0088-2102; 50090-5063; 68022-7055; 53002-1718
UNII XJM390A33U
Synonyms rifapentine | 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin | 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin SV | DL 473-IT | Rifapex | Priftin | DL 473 | DL-4-73 | MDL 473
Chemical Information
Molecular Formula C47H64N4O12
CAS Registry Number 61379-65-5
SMILES CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C) OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C6CCCC6)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vulvovaginal candidiasis11.03.03.005; 21.14.02.003---
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Protein urine present13.13.02.006---
Musculoskeletal discomfort15.03.04.001---
Vulvovaginal pruritus21.08.02.004; 23.03.12.009---
Rectal tenesmus07.03.03.001; 15.05.03.011---
Lung neoplasm malignant16.19.02.001; 22.08.01.001---
Vasodilation procedure25.03.01.001---
Congenital eye disorder03.01.01.002; 06.08.03.011---
Angiopathy24.03.02.007---
Blood alkaline phosphatase increased13.04.02.004--
Porphyrin metabolism disorder03.08.01.006; 09.01.10.004; 14.14.01.006---
Decreased appetite08.01.09.028; 14.03.01.005--
Ill-defined disorder08.01.03.049---
Hyperlipidaemia14.08.03.001--
Increased bronchial secretion22.12.01.002---
Cystitis noninfective20.03.02.001--
Breath sounds abnormal13.15.01.008---
Bronchial hyperreactivity22.03.01.016---
Anorectal discomfort07.03.03.003---
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Product contamination with body fluid27.02.01.001---
Oesophageal irritation07.08.05.004---
Liver function test increased13.03.04.031---
Cross sensitivity reaction10.01.01.0360.001027%-
Vulvovaginal inflammation21.14.02.014---
The 8th Page    First    Pre   8    Total 8 Pages